Vanguard Personalized Indexing Management LLC Sells 2,803 Shares of Stryker Corporation $SYK

Vanguard Personalized Indexing Management LLC lessened its holdings in Stryker Corporation (NYSE:SYK) by 5.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,667 shares of the medical technology company’s stock after selling 2,803 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Stryker were worth $17,456,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Venture Visionary Partners LLC lifted its holdings in Stryker by 9.9% during the 4th quarter. Venture Visionary Partners LLC now owns 6,351 shares of the medical technology company’s stock worth $2,340,000 after purchasing an additional 572 shares in the last quarter. Perryman Financial Advisory Inc. AD purchased a new stake in Stryker during the 4th quarter worth about $453,000. Public Employees Retirement Association of Colorado lifted its holdings in Stryker by 401.2% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 218,695 shares of the medical technology company’s stock worth $76,865,000 after purchasing an additional 175,060 shares in the last quarter. Resources Management Corp CT ADV lifted its holdings in Stryker by 4,557.4% during the 4th quarter. Resources Management Corp CT ADV now owns 21,424 shares of the medical technology company’s stock worth $7,530,000 after purchasing an additional 20,964 shares in the last quarter. Finally, Sargent Investment Group LLC purchased a new stake in Stryker during the 4th quarter worth about $337,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

SYK opened at $312.14 on Monday. The stock’s 50 day simple moving average is $316.40 and its 200 day simple moving average is $343.79. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87. The firm has a market cap of $119.66 billion, a price-to-earnings ratio of 36.13, a PEG ratio of 1.97 and a beta of 0.78.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter last year, the business posted $2.84 EPS. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts predict that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is presently 40.74%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. JPMorgan Chase & Co. lowered their price target on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Wells Fargo & Company lowered their price target on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price target on Stryker in a report on Friday, May 1st. Finally, Citigroup lowered their price target on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $395.33.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.